UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

The New England journal of medicine, 2013-09, Vol.369 (11), p.1023-1034

2013

Link zum Volltext

Verfügbarkeit prüfen

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Journal for immunotherapy of cancer, 2019-10, Vol.7 (1), p.275-275, Article 275

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

BMC cancer, 2019-02, Vol.19 (1), p.122-122, Article 122

2019

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC

Journal of thoracic oncology, 2020-02, Vol.15 (2), p.190-202

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-03, Vol.29 (8), p.1075-1082

2011

Link zum Volltext

Verfügbarkeit prüfen

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Breast cancer research and treatment, 2018-02, Vol.167 (3), p.671-686

2018

Link zum Volltext

Verfügbarkeit prüfen

Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Journal of clinical oncology, 2008-03, Vol.26 (7), p.1040-1050

2008

Link zum Volltext

Verfügbarkeit prüfen

Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with locally advanced or metastatic solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3097-3097

2023

Link zum Volltext

Verfügbarkeit prüfen

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

Breast cancer research and treatment, 2021-11, Vol.190 (2), p.265-275

2021

Link zum Volltext

Verfügbarkeit prüfen

Febrile neutropenia FN-risk chemotherapy: results from a prospective observational study

Supportive care in cancer, 2019-04, Vol.27 (4), p.1449

2019

Link zum Volltext

Verfügbarkeit prüfen

Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin’s lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study

Supportive care in cancer, 2019-04, Vol.27 (4), p.1449-1457

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2008-06, Vol.3 (6), p.623-630

2008

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics and exposure-safety relationship of nanoliposomal irinotecan (MM-398, nal-IRI) in patients with solid tumors

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e13588-e13588

2015

Link zum Volltext

Verfügbarkeit prüfen

Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3620-3620

2013

Link zum Volltext

Verfügbarkeit prüfen

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3511-3511

2013

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC)

Annals of oncology, 2013-06, Vol.24, p.iv23-iv24

2013

Link zum Volltext

Verfügbarkeit prüfen

Liver adenomatosis mimics metastatic liver involvement on FDG-PET/ CT

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2023, Vol.36 (2), p.143

2023

Link zum Volltext

Verfügbarkeit prüfen

P2.06-033 Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects with Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1091-S1092

2017

Link zum Volltext

Verfügbarkeit prüfen

P2.06-033 Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects with Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy: Topic: Supportive, Preventive

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1091-S1092

2017

Link zum Volltext

Verfügbarkeit prüfen

P1.50: Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects With Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S214-S215

2016

Link zum Volltext

Verfügbarkeit prüfen

P1.50: Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects With Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy: Track: Supportive Care and Others

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S214-S215

2016

Link zum Volltext

Verfügbarkeit prüfen

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study

Journal of clinical oncology, 2008-03, Vol.26 (7), p.1040-1050

2008

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of adrenalectomy in patients with primary hyperaldosteronism--a single centre experience

Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2014-12, Vol.158 (4), p.583-590

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Humans
(13)
Female
(10)
Oncology
(10)
Middle Aged
(9)
Aged
(8)
Adult
(7)
Male
(7)
Tumors
(7)
Treatment Outcome
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Breast Cancer
(5)
Chemotherapy
(5)
Disease-Free Survival
(5)
Metastasis
(5)
Aged, 80 And Over
(4)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(4)
Biological And Medical Sciences
(4)
Cancer
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC

Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with locally advanced or metastatic solid tumors

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

Febrile neutropenia FN-risk chemotherapy: results from a prospective observational study

Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin’s lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study

Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

Population pharmacokinetics and exposure-safety relationship of nanoliposomal irinotecan (MM-398, nal-IRI) in patients with solid tumors

Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC)

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC)

Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC)

Liver adenomatosis mimics metastatic liver involvement on FDG-PET/ CT

P2.06-033 Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects with Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy

P2.06-033 Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects with Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy: Topic: Supportive, Preventive

P1.50: Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects With Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy

P1.50: Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects With Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy: Track: Supportive Care and Others

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study

Outcomes of adrenalectomy in patients with primary hyperaldosteronism--a single centre experience

Suchergebnisse filtern